Similarly, combination treatment with EZH2 inhibitors such as GSK126 [48, 49] may further increase therapeutic efficacy and due to potential synergistic effects decrease JQ1 dose levels required for successful treatment of ES. The gene discussed is EZH2; the disease is Ewing sarcoma.